David T Maclaughlin

US Patent:

6692738, Feb 17, 2004

Filed:

Jan 26, 2001

Appl. No.:

09/770339

Inventors:

David T. MacLaughlin - Saugus MA
Joseph P. Vacanti - Winchester MA
Patricia K. Donahoe - Boston MA
Peter T. Masiakos - Boston MA

Assignee:

The General Hospital Corporation - Boston MA

International Classification:

A61K 4800

US Classification:

424 9321, 424484, 435455, 435325

Abstract:

Normal cells, such as fibroblasts or other tissue or organ cell types, are genetically engineered to express biologically active, therapeutic agents, such as proteins that are normally produced in small amounts, for example, MIS, or other members of the TGF-beta family Herceptinâ, interferons, andanti-angiogenic factors. These cells are seeded into a matrix for implantation into the patient to be treated. Cells may also be engineered to include a lethal gene, so that implanted cells can be destroyed once treatment is completed. Cells can be implanted in a variety of different matrices. In a preferred embodiment, these matrices are implantable and biodegradable over a period of time equal to or less than the expected period of treatment, when cells engraft to form a functional tissue producing the desired biologically active agent. Implantation may be ectopic or in some cases orthotopic. Representative cell types include tissue specific cells, progenitor cells, and stem cells.

US Patent:

7078032, Jul 18, 2006

Filed:

Oct 21, 2003

Appl. No.:

10/690077

Inventors:

David T. MacLaughlin - Saugus MA, US
Joseph P. Vacanti - Winchester MA, US
Patricia K. Donahoe - Boston MA, US
Peter T. Masiakos - Boston MA, US

Assignee:

The General Hospital Corporation - Boston MA

International Classification:

A61K 48/00
A61K 9/14
A01N 63/00
C12N 5/00
C12N 15/63
C12P 21/06
C12N 15/00

US Classification:

424 9321, 424 931, 424 932, 424484, 435 691, 4353201, 435325, 435455

Abstract:

Normal cells, such as fibroblasts or other tissue or organ cell types, are genetically engineered to express biologically active, therapeutic agents, such as proteins that are normally produced in small amounts, for example, MIS, or other members of the TGF-beta family Herceptin™, interferons, and anti-angiogenic factors. These cells are seeded into a matrix for implantation into the patient to be treated. Cells may also be engineered to include a lethal gene, so that implanted cells can be destroyed once treatment is completed. Cells can be implanted in a variety of different matrices. In a preferred embodiment, these matrices are implantable and biodegradable over a period of time equal to or less than the expected period of treatment, when cells engraft to form a functional tissue producing the desired biologically active agent. Implantation may be ectopic or in some cases orthotopic. Representative cell types include tissue specific cells, progenitor cells, and stem cells.

US Patent:

7241577, Jul 10, 2007

Filed:

Aug 20, 2002

Appl. No.:

10/225503

Inventors:

David B. Seifer - Holmdel NJ, US
David T. MacLaughlin - Saugus MA, US

Assignee:

University of Medicine and Dentistry of New Jersey - New Brunswick NJ
The General Hospital Corporation - Boston MA

International Classification:

G01N 33/53
C07K 14/00

US Classification:

435 71, 435 721, 435 792, 436501, 530397, 530399

Abstract:

Methods and kits are provided for assessing the ovarian reserve and predicting the ovarian response to fertility treatments in a female subject. The serum levels of MIS are shown to be positively correlated with the production and retrieval of mature oocytes and serve as prognostic indicators for the female response to fertility treatment. The MIS levels can be monitored prior to and during fertility treatment and are useful to adjust the timing and dosage of treatments in order to produce optimal outcome in individual patients, to avoid ovarian hyperstimulation, or to indicate cancellation of an unsuccessful treatment. MIS can also be administered to women to stimulate follicle development and to prevent depletion of ovarian reserve.

US Patent:

7427486, Sep 23, 2008

Filed:

Jun 29, 2007

Appl. No.:

11/824154

Inventors:

David B. Seifer - Holmdel NJ, US
David T. MacLaughlin - Saugus MA, US

Assignee:

University of Medicine and Dentistry of New Jersey - New Brunswick NJ
The General Hospital Corporation - Boston MA

International Classification:

G01N 33/00
G01N 33/53
C07K 14/00

US Classification:

435 71, 435 721, 435 792, 436501, 530397, 530399

Abstract:

Methods and kits are provided for assessing the ovarian reserve and predicting the ovarian response to fertility treatments in a female subject. The serum levels of MIS are shown to be positively correlated with the production and retrieval of mature oocytes and serve as prognostic indicators for the female response to fertility treatment. The MIS levels can be monitored prior to and during fertility treatment and are useful to adjust the timing and dosage of treatments in order to produce optimal outcome in individual patients, to avoid ovarian hyperstimulation, or to indicate cancellation of an unsuccessful treatment. MIS can also be administered to women to stimulate follicle development and to prevent depletion of ovarian reserve.

US Patent:

20100273160, Oct 28, 2010

Filed:

Jul 17, 2008

Appl. No.:

12/669136

Inventors:

Patricia K. Donahoe - Boston MA, US
Paul P. Szotek - Indianapolis IN, US
David T. MacLaughlin - Gloucester MA, US
Frederic Preffer - Cambridge MA, US
David Michael Dombkowski - Cambridge MA, US

Assignee:

THE GENERAL HOSPITAL CORPORATION - Boston MA

International Classification:

C12Q 1/04
C12N 5/09
C12Q 1/02
C12Q 1/68

US Classification:

435 6, 435366, 435 34, 435 29

Abstract:

The present invention relates to compositions and methods for treating, characterizing and diagnosing ovarian cancer. In particular, the present invention provides methods for treating and/or preventing ovarian cancer in a subject by administering to the subject an effective amount of Mullerian Inhibiting substance and/or an effective amount of an agent that inhibits BCRP1. The present invention further provides methods to identify and/or enrich for populations of ovarian cancer stem cells and populations of somatic ovarian stem cells, in particular, enrichment for populations of coelomic somatic ovarian stem cells, subcoelomic/stromal somatic ovarian stem cells and periphilar medullary somatic ovarian stem cells. The present invention also provides somatic ovarian stem cell markers and ovarian cancer stem cell markers, as well as methods to identify agents which selectively inhibit the proliferation of ovarian cancer stem cells as compared to somatic ovarian stem cells.

US Patent:

20140194366, Jul 10, 2014

Filed:

Jun 1, 2012

Appl. No.:

14/123551

Inventors:

Patricia K. Donahoe - Boston MA, US
David T. MacLaughlin - Gloucester MA, US
Jose Teixeira - Grand Rapids MA, US

Assignee:

THE GENERAL HOSPITAL CORPORATION - Boston MA

International Classification:

G01N 33/574

US Classification:

514 193, 435 723, 435 29

Abstract:

The present invention generally relates to methods, assays, compositions and kits related to a subpopulation of ovarian cancer stem cells which are selected or enriched by chemotherapeutic agents and inhibited by MIS (Mullerian Inhibiting Substance) and MIS mimetics. In particular, the present invention relates to a population of CD44+/CD24+/EpCam+/ECad− subpopulation of ovarian cancer stem cells. The present invention also provides methods to screen a subject with ovarian cancer to identify if they have an ovarian cancer comprising CD44+/CD24+/EpCam+/ECad− ovarian cancer stem cells, and methods to identify and enrich or isolate for such ovarian cancer cell populations.